ArticleResearch and practice in thrombosis and haemostasis2025
Hetrombopag for patients with persistent primary immune thrombocytopenia: a post hoc analysis of a multicenter, randomized phase Ⅲ trial.
Article in Research and practice in thrombosis and haemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03222843 (A Phase III,Multicentre, Randomized, Double-Blind and Open-Label Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Patients With Idiopathic Thrombocytopenic Purpura), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase III,Multicentre, Randomized, Double-Blind and Open-Label Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Patients With Idiopathic Thrombocytopenic Purpura
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hetrombopag has been approved for chronic ITP (duration >12 months). However, its efficacy and safety in persistent ITP (duration 3-12 months) remain unexplored. Objectives: This post-hoc analysis aimed to evaluate the efficacy and safety of hetrombopag in persistent ITP patients and compare outcomes with chronic ITP and overall ITP patients, based on existing clinical data. Methods: Data were derived from a registration phase Ⅲ trial (NCT03222843), which included a 10-week randomized, double-blind, placebo-controlled treatment period (initial dose: hetrombopag 2.5 mg as HETROM-2.5 group, hetrombopag 5.0 mg as HETROM-5.0 group, or placebo once daily), a 14-week open-label treatment period, a dose tapering to withdrawal period and a 24-week single-arm extension period. The primary endpoint was the proportion of responders (a platelet count of ≥ 50 × 10 Results: Of 395 who completed the double-blinded treatment, 80 patients had persistent ITP. The proportion of patients with persistent ITP who achieved primary endpoint was 68.8% in the HETROM-2.5 group and 74.3% in the HETROM-5.0 group, significantly higher than 7.7% in the placebo group. Hetrombopag also demonstrated other therapeutic benefits over placebo including reduced bleeding risk and rescue therapy need. Similar efficacy results were observed in both the chronic ITP and the overall ITP population. Furthermore, hetrombopag manifested favorable safety profile in patients with persistent ITP, and safety outcomes were comparable with those in chronic and overall ITP populations. Conclusion: Hetrombopag showed favorable safe and efficacy profile in patients with persistent ITP, aligning with results observed in patients with chronic ITP and overall ITP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.